

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEApplicant: **Himanshu BRAHMBHATT et al.**Title: ***METHODS FOR TARGETED IN VITRO AND IN VIVO DRUG DELIVERY TO MAMMALIAN CELLS VIA BACTERIALLY DERIVED INTACT MINICELLS (as amended)***Appl. No.: **10/588,028**International Filing Date: **1/27/2005**371(c) Date: **4/30/07**Examiner: **Anoop Kumar Singh**Art Unit: **1632**Confirmation Number: **1320****SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56**

Mail Stop After Final
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of a document known to applicant in order to comply with applicant's duty of disclosure pursuant to 37 C.F.R. §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 C.F.R. §1.56(b). Applicant does not waive any right to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed document is being submitted in compliance with 37 C.F.R. §1.97(d), after a final office action but before payment of the issue fee.

Applicant requests that the listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

STATEMENT

The undersigned hereby states in accordance with 37 C.F.R. §1.97(e)(1) that the item of information contained in this supplemental information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to filing of this Statement.

FEE

Fees in the amount of \$180.00 to cover the fee associated with an information disclosure statement under 37 C.F.R. §1.97(d) are being paid by credit card via EFS-Web.

The Commissioner is hereby authorized to charge any additional fee which may be required regarding this submission under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment instructions in EFS-Web being incorrect or absent, resulting in a rejected or incorrect credit card transaction, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date February 18, 2010

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (617) 342-4039
Facsimile: (617) 342-4001

By R. Brian McCaslin

R. Brian McCaslin
Attorney for Applicant
Registration No. 48,571